Clinical Trial Update: Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating TXA127 (Angiotensin 1-7) to improve engraftment in pediatric cord blood transplantation was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancy
• Inherited Metabolic Disorder

Drugs mentioned

• TXA127 (Angiotensin 1-7) (Angiotensin 1-7)

Snippet

Sponsor: Tarix Pharmaceuticals | Conditions: Cord Blood Transplant, Hematologic Malignancy | Phase 2 | Status: WITHDRAWN